NLRB General Counsel Jennifer Abruzzo issued a memo to all field offices clarifying the board’s recent ruling in a case regarding severance agreements.
NLRB Rules Severance Agreements with Nondisclosure Clauses are Unlawful Read More »
Noticias de la actualidad científica y tecnológica del 3 de abril de 2023. …
Luxna Biotech Co., Ltd. (President & CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) today announced that it has entered into a collaboration agreement with Servier, a global pharmaceutical group, (President: Olivier Laureau, Headquarters: Suresnes, France, hereinafter “Servier”) for drug discovery research in the field of neurological diseases.
Luxna Announces Collaboration Agreement for Drug Discovery Research with Servier Read More »
Phase III data for Pfizer’s respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants.
Pfizer Publishes Phase III RSV Data Ahead of May Decision Read More »
QurAlis Corporation today announced that the first patient has been dosed in its Phase 1 clinical trial of QRL-201 for the treatment of ALS (ANQUR).
Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated.
Vistagen (NASDAQ: VTGN) today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.
Vistagen Receives New European Patent for AV-101 Read More »
restor3d, a research-driven medical device company, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Axiom PSR System for use with the company’s Kinos Axiom Total Ankle System.
Labcorp, a leading global life sciences company, announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
Labcorp Declares Quarterly Dividend – April 06, 2023 Read More »
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced it has entered into a term loan financing facility for up to $175 million with entities managed by Pharmakon Advisors, LP.
